CD28 and neoplasm: Focusing on NSCLC, then we evaluated the dynamic distribution and functionality of PD1+CD28− and PD1+CD28+ T-cell subsets in 68 treatment-naïve NSCLC patients (Table S1), by comparing peripheral blood, adjacent non-tumor (NT) tissue and tumor site (T) (n = 32 matched NSCLC patients).